Welcome to our dedicated page for Anebulo Pharmaceuticals news (Ticker: ANEB), a resource for investors and traders seeking the latest updates and insights on Anebulo Pharmaceuticals stock.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) is a clinical-stage pharmaceutical company developing selonabant (ANEB-001), a CB1 receptor antagonist drug candidate for acute cannabis-induced toxicity and related cannabinoid-induced toxic effects. The ANEB news feed on Stock Titan aggregates the company’s press releases and market-moving updates so readers can follow how its development and corporate plans evolve over time.
News about Anebulo frequently centers on its clinical program for selonabant. The company has reported results from a Phase 2 proof-of-concept trial of oral selonabant in adults challenged with oral THC, as well as the initiation of a Phase 1 single ascending dose study of an intravenous formulation in healthy young adults. Updates often describe study design, safety and tolerability observations, and the role of selonabant as a potential antidote for acute cannabis-induced toxicity, particularly in pediatric patients.
Investors and observers can also find regulatory and funding developments in Anebulo’s news. The company has announced interactions with the U.S. Food and Drug Administration regarding the development path for IV selonabant, grant awards from the National Institute on Drug Abuse (NIDA) to support its clinical work, and private placement financings and loan arrangements that provide capital for ongoing research and development.
Another recurring theme in ANEB news is the company’s strategic and corporate actions, including a proposed going private transaction, a previously announced reverse stock split structure, and a later decision to pursue a voluntary self-tender offer to repurchase shares as part of its plan to reduce the number of stockholders. By reviewing the ANEB news page, readers can track clinical milestones, regulatory interactions, grant funding, financing events, and corporate governance decisions that Anebulo discloses through its press releases.
Anebulo Pharmaceuticals (NASDAQ: ANEB) reported its Q3 FY2025 financial results and provided updates on its clinical development program. The company is advancing intravenous selonabant as a potential treatment for pediatric patients with cannabis-induced Central Nervous System (CNS) depression. Anebulo plans to initiate a Phase 1 single ascending dose (SAD) study in healthy adult volunteers aged 18-25 years in Q3 2025.
Financial highlights include operating expenses of $1.9 million (vs $1.7M in Q3 FY2024), a net loss of $1.7 million or $(0.04) per share, and cash and cash equivalents of $13.3 million as of March 31, 2025. The company has access to an additional $3 million through a Loan Agreement.
Anebulo Pharmaceuticals (ANEB) reported Q2 FY2025 financial results and updates on their lead product candidate, selonabant, designed to treat acute cannabis-induced toxic effects. The company secured $15 million through a private placement of 15.2 million shares and amended its Loan Security Agreement to $3 million.
Key developments include FDA discussions regarding intravenous selonabant development, with the agency acknowledging the unmet need for treating cannabis toxicity in children. The company plans to begin Phase 1 single ascending dose study in 1H25.
Financial results show operating expenses of $2.6 million in Q2 FY2025, down from $2.8 million year-over-year. Net loss was $2.5 million ($0.09 per share) compared to $2.7 million ($0.11 per share) in Q2 FY2024. Cash position stands at $15.0 million as of December 31, 2024.
Anebulo Pharmaceuticals (ANEB) announced positive regulatory progress for selonabant in treating acute cannabis-induced toxicity in children and secured a $15 million capital raise. The company's Phase 2 proof-of-concept study with 134 adult subjects demonstrated that oral selonabant effectively blocked or reversed key CNS effects of THC. The FDA acknowledged the unmet need for treating children exposed to cannabis toxicity and proposed ongoing collaboration.
The company secured a private placement of 15.2 million shares at $0.99 per share, priced at-the-market under Nasdaq rules. Additionally, Anebulo will modify its Loan and Security Agreement, reducing the maximum loan size to approximately $3 million. The company plans to initiate a Phase I SAD study of IV selonabant in healthy adults in first half of 2025.
Anebulo Pharmaceuticals (ANEB) has reported its Q1 FY2025 financial results and updates. The company received the first tranche of a $1.9 million NIDA grant to advance its intravenous selonabant formulation for treating acute cannabis-induced toxicities. The company plans to complete IND-enabling activities by end of 2024 and enroll first volunteers in H1 2025. Financial results show operating expenses of $2.4 million, with a net loss of $2.2 million ($0.08 per share). Cash position stands at $1.4 million, with access to an additional $10 million through a recent Loan Agreement.
Anebulo Pharmaceuticals (Nasdaq: ANEB) reported financial results for Q4 and FY 2024, ending June 30, 2024. Key highlights include:
1. Awarded first tranche of a $1.9 million grant from NIDA/NIH
2. Prioritizing development of selonabant IV formulation for unintentional cannabis poisoning in children
3. Q4 FY2024 operating expenses: $1.3 million (vs $2.5 million in Q4 FY2023)
4. Q4 FY2024 net loss: $1.3 million or $(0.05) per share
5. FY2024 operating expenses: $8.3 million (vs $11.8 million in FY2023)
6. FY2024 net loss: $8.2 million or $(0.32) per share
7. Cash and cash equivalents: $3.1 million as of June 30, 2024
8. Access to additional $10 million through Loan and Security Agreement
Anebulo Pharmaceuticals (Nasdaq: ANEB) has been awarded a two-year cooperative grant of up to $1.9 million from the National Institute on Drug Abuse (NIDA) to support the development of intravenous selonabant. This potential emergency treatment targets acute cannabis-induced toxicities, particularly cannabis-induced CNS depression in children.
The grant is structured in two tranches: an initial $0.9 million award, followed by approximately $1 million subject to meeting certain milestones. This funding acknowledges the growing unmet medical need for a cannabis antidote, especially for children who are more susceptible to cannabis toxicity due to their underdeveloped endocannabinoid system.
Anebulo's CSO, Ken Cundy, emphasized that this grant provides validation for their work, while CEO Richie Cunningham highlighted how it aligns with their recent decision to prioritize the development of the intravenous formulation of selonabant.
Anebulo Pharmaceuticals (Nasdaq: ANEB) reported financial results for Q3 fiscal year 2024 and provided updates on its development projects.
Key focus is on the IV formulation of selonabant for unintentional cannabis poisoning in children, driven by a growing medical need and upcoming DEA reclassification of marijuana. The company's operating expenses dropped to $1.7 million from $2.9 million year-over-year. Net loss decreased to $1.7 million, or $(0.06) per share, from $2.8 million, or $(0.11) per share. As of March 31, 2024, the company holds $5.1 million in cash and cash equivalents.
Summary not available.
Summary not available.
Summary not available.